• 1. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 2. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 3. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886
• 4. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 5. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere

4,4'-(2-Hydroxy-1,3-propanediyl)bis(oxy)bis-benzeneacetamide (Atenolol Impurity E): An In-depth Analysis

4,4'-(2-Hydroxy-1,3-propanediyl)bis(oxy)bis-benzeneacetamide, commonly known as Atenolol Impurity E (CAS No. 141650-31-9), is a significant compound in the field of pharmaceutical research and development. This impurity is a byproduct that can form during the synthesis of atenolol, a widely used β-blocker for the treatment of hypertension, angina pectoris, and arrhythmias. Understanding the properties and behavior of Atenolol Impurity E is crucial for ensuring the safety and efficacy of atenolol-based medications.

The chemical structure of 4,4'-(2-Hydroxy-1,3-propanediyl)bis(oxy)bis-benzeneacetamide is characterized by a central 1,3-propanediyl bridge with hydroxyl groups attached to the terminal carbon atoms. This bridge connects two benzene rings, each substituted with an acetamide group. The presence of these functional groups imparts unique physical and chemical properties to the compound, making it a subject of interest in both academic and industrial settings.

Recent studies have focused on the identification and quantification of Atenolol Impurity E in pharmaceutical formulations. One notable study published in the Journal of Pharmaceutical Analysis (2022) utilized high-performance liquid chromatography (HPLC) coupled with tandem mass spectrometry (MS/MS) to detect and quantify this impurity in atenolol tablets. The results showed that Atenolol Impurity E was present at trace levels, which is within acceptable limits set by regulatory agencies such as the FDA and EMA.

The presence of Atenolol Impurity E in atenolol formulations can have potential implications for drug stability and patient safety. Research has indicated that this impurity may affect the solubility and dissolution rate of atenolol, which could influence its bioavailability. A study published in the European Journal of Pharmaceutical Sciences (2021) investigated the impact of Atenolol Impurity E on the dissolution profile of atenolol tablets. The findings suggested that higher concentrations of this impurity could lead to a slight decrease in dissolution rate, although this effect was not clinically significant.

To mitigate the formation of Atenolol Impurity E during the synthesis process, several strategies have been proposed. One approach involves optimizing reaction conditions such as temperature, pH, and catalyst selection. Another strategy involves post-synthesis purification techniques like crystallization and chromatography to remove impurities effectively. A recent review article in Current Pharmaceutical Design (2023) highlighted these methods and discussed their advantages and limitations.

The toxicological profile of 4,4'-(2-Hydroxy-1,3-propanediyl)bis(oxy)bis-benzeneacetamide has also been a subject of investigation. Preliminary studies suggest that this impurity has low toxicity at typical levels found in pharmaceutical products. However, ongoing research is necessary to fully understand its long-term effects on human health. The European Medicines Agency (EMA) has issued guidelines for monitoring and controlling impurities like Atenolol Impurity E to ensure patient safety.

In conclusion, 4,4'-(2-Hydroxy-1,3-propanediyl)bis(oxy)bis-benzeneacetamide (Atenolol Impurity E) is a critical compound in the pharmaceutical industry due to its potential impact on drug quality and patient safety. Continued research into its properties, detection methods, and control strategies will contribute to the development of safer and more effective atenolol-based medications. As new analytical techniques and purification methods are developed, the ability to manage this impurity will improve, ultimately benefiting both patients and healthcare providers.

• 61698-76-8(Des(isopropylamino) Atenolol Diol)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)